ImmunityBio, Inc.（IBRX）在夜盘交易中股价大跌5.63%，引发市场关注。这家临床阶段生物科技公司今日早些时候公布了2025财年第一季度财务报告，显示公司仍面临巨额亏损。
根据财报，ImmunityBio第一季度净亏损为1.30亿美元，虽然较去年同期略有改善，同比减少亏损2.99%，但仍然处于大幅亏损状态。公司营收为1652万美元，同比大幅增长41200%，但这一增长似乎未能抵消投资者对持续亏损的担忧。每股基本亏损为0.15美元。
从资产负债情况来看，ImmunityBio的财务状况仍然面临挑战。公司总负债达8.94亿美元，其中短期债务为746万美元。资产负债比为0.35，流动比率仅为0.03，显示公司的短期偿债能力较弱。尽管有5家机构对公司股票给出了平均11.25美元的目标价，但投资者似乎对公司的财务状况和未来前景持谨慎态度。夜盘的大幅下跌可能反映了市场对公司财务状况的担忧，尽管具体原因还需进一步观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.